Perceptions and attitudes of community pharmacists towards generic medicines. by Dunne, Suzanne S. et al.
1138 Journal of Managed Care & Specialty Pharmacy JMCP November 2014 Vol. 20, No. 11 www.amcp.org
Perceptions and Attitudes of Community 
Pharmacists Towards Generic Medicines
Suzanne S. Dunne, BSc (Hons), MSc; Bill Shannon, MD, FRCGP, MICGP;  
Walter Cullen, MD, MICGP, MRCGP; and Colum P. Dunne, BSc (Hons), MBA, PhD
ABSTRACT
BACKGROUND: Following the enactment of legislation in June 2013, generic 
substitution and reference pricing of medicines has been introduced, for 
the first time, in Ireland. This novel study is the first assessment of the per-
ceptions of community pharmacists in Ireland towards generic medicines 
completed in the period immediately prior to the introduction of generic 
substitution and reference pricing. 
OBJECTIVE: To determine the perceptions towards generic medicines 
among community pharmacists.
METHODS: One-to-one semistructured interviews were performed with a 
convenience sample of 44 community pharmacists (from approximately 
4,500 pharmacists in Ireland) recruited from Ireland’s Midwest, South, and 
Southwest regions. Interviews were transcribed and analysed using NVivo 
(version 9).
RESULTS: 98% of pharmacists believed that generics were of a similar 
quality to the originator, and 96% stated that they were as effective as 
the originator. However, a small number demonstrated some reticence 
regarding generics: 9% believed that generics were not manufactured to 
the same quality as the originator; 7% stated they would prefer to take 
an originator medicine themselves; and 7% reported having experienced 
quality issues with generic medicines. 89% of pharmacists reported receiv-
ing patient complaints regarding use of generic medicine, although 64% 
suggested that this was due to a nocebo effect (i.e., a result of patients’ 
preconceived notions that generics were inferior). Only a minority (21%) 
reported that they had attempted to educate patients as to the equivalency 
of generics. Although 80% were in favor of Ireland’s new legislation pro-
moting the use generic medicines, 46% expressed concerns regarding its 
practical implementation.
CONCLUSIONS: This key stakeholder group had positive attitudes towards 
generics and the legislation that promotes their use. Concerns regarding 
patient perception and experience, clinical effectiveness, and manufactur-
ing quality were identified. We propose that interventions supporting imple-
mentation of the new legislation should address these concerns.
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RESEARCH
In June 2013, new legislation came into effect in Ireland
1—
the Health (Pricing and Supply of Medical Goods) Act 
2013)2—that introduced generic substitution and reference 
pricing for the first time in this country. As a result of this 
new legislation, Irish patients will now have a greater oppor-
tunity to receive a generic medicine instead of a brand-name 
prescription medication. In an effort to ensure that this leg-
islation is successful, pharmacists’ opinions of, and attitudes 
towards, generic medicines are critical to the changes being 
implemented—that is, to increase the use of generic medicines 
in Ireland. 
Attitudes of Irish pharmacists towards generics have not 
been published in the past. While assessments of pharmacist 
perceptions of generic medicines have been carried out in a 
limited number of other countries, a PubMed search covering 
the period from January 2003 to January 2014 did not return 
any peer-reviewed publications on the topic of pharmacist 
perceptions of generic medicines in Ireland. In fact, only 10 
publications since 2003 were found in PubMed on the topic 
of pharmacist perceptions of, and attitudes towards, generic 
• Pharmacist perceptions of, and attitudes towards, generic medi-
cines are a relatively unexplored area internationally, with only 
10 publications found in PubMed on this topic since 2003.
• No studies of the views of community pharmacists in Ireland 
towards generic medicines have ever been published.
What is already known about this subject
• This is the first study of pharmacist perceptions of generic 
medicines in Ireland and 1 of only 6 other studies on pharmacist 
perceptions of generics in Europe.
•	This is only the second qualitative investigation of pharmacist 
views in Europe—the other being from Sweden and published in 
2012.
• This study adds to the body of knowledge on pharmacist attitudes 
towards generics, providing in-depth, qualitative data that can be 
used as a basis for policy implementation and decision making.
What this study adds
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one interviews were carried out with consenting pharmacists 
between June and October 2012: 34 face to face and 10 via tele-
phone. Interview lengths were as follows: minimum 10 min-
utes 44 seconds; maximum 36 minutes and 15 seconds; mean 
19 minutes 29 seconds. Interviews that were recorded (with 
the interviewee’s consent) were semistructured and based on 
the described study instrument (see Table 1). Additional sup-
porting assessment of opinions was completed using a series 
of structured questions to which participants could select from 
predefined answers (Table 2). In this instance, a 5-point Likert 
scale was used with a single response allowed for each ques-
tion.15 Participants were free to volunteer additional commen-
tary on each question. Furthermore, participants were offered 
the opportunity to express freely any additional opinions or 
views at the end of the interview session. Participating pharma-
cists were located in counties Limerick, Tipperary, Kilkenny, 
Cork, and Waterford.
medicines, indicating that this is a relatively underexplored 
area internationally.3-12
With Ireland on the cusp of a major modification in health 
care practices, there are many potential hurdles to overcome 
during the introduction of such changes.13 The attitudes and 
behaviors of health care professionals towards generic medi-
cines are pivotal to the successful implementation of the new 
legislation. The objective of this novel study was to assess these 
perceptions among community pharmacists in Ireland in the 
time leading up to the enactment of the new legislation and 
to determine what challenges might arise as a result of these 
stakeholder opinions.
■■  Methods
Preparation of Study Instrument
The study instrument was developed based on a recently 
published review of the usage of generic medicines and how 
policy changes to promote the use of generic medicines may 
affect health care provision14 and the personal experience of 
the primary author and study designer (who has over 15 years 
of quality management and regulatory affairs within the phar-
maceutical and biopharmaceutical industry).
Questions for the semistructured interview were prepared 
and validated by cognitive testing, the purpose of which was 
to ensure that the test questions were understood as intended. 
The purpose of the interviews was to elucidate perceptions 
relating to general opinion and understanding of generic medi-
cines; behaviors towards generic medicines (e.g., dispensing 
behaviors in the case of community pharmacists); opinions 
as to the historical poor usage of generics in Ireland; beliefs 
held as to the quality and efficacy of generics and how these 
compare with proprietary (that is, brand-name) medicines; and 
knowledge and opinion of the impending legislative change.
Cognitive testing was performed with 3 individuals who 
were first asked the questions to be included in the survey, 
allowed to provide responses, and after responding were asked 
what their understanding of the questions were. Amendments 
were made to questions based on responses from all 3 test par-
ticipants. The responses of these participants to the interview 
questions were not included in those finally analysed for this 
study. The interviews used in the study began after cognitive 
testing had been completed, and the interview questions had 
been amended. 
Sampling, Recruitment, and Interviews
A convenience sample of community pharmacists was 
recruited, and interviews completed and analysed. Pharmacists 
were approached in person, while in the pharmacy, and invited 
to participate in the study. A verbal explanation of the study 
was provided, and an invitation letter was offered. One-to-
What is your understanding of what a generic medicine is?
What is your understanding of how a generic medicine differs from an origi-
nator medicine?
What is your understanding of bioequivalence?
To the best of your knowledge, what percentage of difference is allowed in 
terms of bioequivalence between an originator medicine and an equivalent 
generic product?
What is your understanding of why generic medicines are cheaper than 
originator medicines?
What do you believe about how generic medicines compare with brand- 
name medicines?
What is your opinion as to why use of generic drugs in Ireland has histori-
cally been much lower than other European countries?
Have you ever had a patient report that a generic medicine, which you dis-
pensed for them, did not work as effectively as an originator medicine?
If yes, what type of medicine(s) have you seen this with?
Can you please give some brief details of what the patient reported having 
experienced?
What action did you take in this case?
Did you then dispense the originator medicine?
If yes, was there any reported lack of efficacy from the substituted origi-
nator medicine?
Have you ever had a patient report that an originator medicine, which you 
dispensed for them, did not work as effectively as a generic medicine?
If yes, what type of medicine(s) have you seen this with?
Can you please give some brief details of what the patient reported having 
experienced?
What action did you take in this case?
Are you aware of the government’s plans to introduce reference pricing and 
generic substitution in Ireland?
What is your opinion of this proposed change in Irish legislation?
TABLE 1 Study Instrument: Questions That 
Formed the Basis for Semistructured 
Interviews
1140 Journal of Managed Care & Specialty Pharmacy JMCP November 2014 Vol. 20, No. 11 www.amcp.org
Perceptions and Attitudes of Community Pharmacists Towards Generic Medicines
Approval of the design and the implementation of this study 
was granted by the Research Ethics Committee of the Irish 
College of General Practitioners.
Analysis of Data
Using a grounded theory approach,16 interviews were tran-
scribed verbatim and imported into NVivo, version 9 (QSR 
International, Melbourne, Australia) for analysis. Using an 
inductive process, transcripts were open coded for themes 
relating to interviewee opinions, perceptions, and behav-
iors, including any other emerging themes, and the results 
were analysed using Nvivo. To facilitate visualization and 
understanding of the numbers of participants holding the 
perceptions/behaviors that were coded into specific themes, 
responses were expressed as a percentage of the total number 
of participants. Interviews were conducted until saturation of 
data was observed. Analysis was completed by the primary 
researcher (SD) and reviewed to ensure reliability and rigor of 
the analysis by a senior investigator (CD). 
The coding framework included (but was not limited to) 
such themes as opinions regarding safety and efficacy; previous 
experience with use of generics; personal preferences; beliefs 
regarding historical usage of generics in Ireland; experiences 
with patient reports regarding generics; prescribing rationales; 
personal knowledge of, and attitudes towards, generic medi-
cines; and opinions regarding the proposed legislative changes. 
Ongoing analysis of themes emerging from the interviews 
was carried out as interviews were completed. When 4 to 5 
consecutive interviews did not lead to the emergence of any 
new themes, it was determined that data saturation had been 
achieved and interviewing was concluded.
■■  Results
Supporting quotations from pharmacists are included in Table 
3, as referenced in the text.
Analyzing Pharmacist Interviews 
Forty-four community pharmacists were interviewed. Demo-
graphics of the group are available in Table 4. Participating 
pharmacists were located in counties Limerick, Tipperary, 
Cork, and Waterford.
Opinions Regarding Quality, Efficacy, and Safety of Generics 
Table 2 shows the analysis of opinions regarding quality, effi-
cacy, and safety of generics. The majority of pharmacists (98%) 
were of the belief that generic medicines are of the same qual-
ity as the originator, with 96% holding the view that they are 
as efficacious as brand-name products. All of the pharmacists 
interviewed believed that generics are as safe as the origina-
tor. A small number (9%), however, were of the opinion that 
generics are not manufactured to the same quality as originator 
medicines and were of the view that generic manufacturing is 
of a poorer standard. The majority of pharmacists (93%) stated 
that they would take a generic medicine themselves, with a 
small number (7%) stating that they would prefer to take the 
originator rather than an equivalent generic, if offered a choice 
(reference quotations 1-3, Table 3).
Do you strongly agree, agree, 
neither agree nor disagree, disagree, 
strongly disagree with the following 
statements:
Pharmacists, N = 44
SA/Aa SD/Db Nc
n % n % n %
Generic medicines are generally of the 
same quality as originator medicines.
43 97.7 1 2.3 0 0.0
Generic medicines are generally poorer 
quality than originator medicines.
1 2.3 42 95.5 1 2.3
Generic medicines are generally better 
quality than originator medicines.
1 2.3 27 61.4 16 36.4
Generic medicines work as effectively  
as originator medicines.
42 95.5 0 0.0 2 4.5
Generic medicines work better than 
originator medicines.
0 0.0 35 79.5 9 20.5
Generic medicines don’t work as well  
as originator medicines.
1 2.3 43 97.7 0 0.0
Generic medicines may be dangerous 
compared with originator medicines.
2 4.5 39 88.6 3 6.8
Generic medicines are as safe as 
originator medicines.
44 100.0 0 0.0 0 0.0
Generic medicines are manufactured 
to the same quality as originator 
medicines.
35 79.5 4 9.1 5 11.4
Generic medicines are manufactured 
to a poorer quality than originator 
medicines.
4 9.1 39 88.6 1 2.3
Generic medicines are manufactured 
to a higher quality than originator 
medicines.
0 0.0 39 88.6 5 11.4
Generic medicines are cheaper to buy 
than originator medicines.
41 93.2 2 4.5 1 2.3
Generic medicines are cheaper because 
they are of inferior quality to originator 
medicines.
1 2.3 43 97.7 0 0.0
If I were ill, I would be happy to 
take a generic medicine if my doctor 
prescribed it for me.
41 93.2 2 4.5 1 2.3
If I were ill, I would prefer to take 
an originator medicine rather than a 
generic medicine, even if it is more 
expensive.
3 6.8 39 88.6 2 4.5
aStrongly agree/agree.
bStrongly disagree/disagree. 
cNeutral/no opinion.
TABLE 2 Study Instrument: Supporting 
Structured Questions and 
Pharmacist Responses 
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Quotation 
Number Quotation
1 To be honest . . . for any decisions that I make, or anything I say to customers, if it was me or any of my family and I was given the option of a generic medi-
cine I would go for it, I would absolutely take it. Female, aged 30-39 years
2 I believe that they are equivalent in therapeutic value, and I would have no hesitation in recommending a generic product over a branded one to a customer. 
Male, aged 19-29 years
3 I think generic medications are brilliant. To be honest with you, the only downside is people’s perceptions—they think that the brands are better when in 
reality generics are just as good. Male, aged 18-29 years
4 On paper they should be the same and should act in the same way, but we have had cases where people have come in and said that they didn’t find a generic as 
effective as the original and they prefer the original . . . and from customers’ queries, some of them don’t find that they’re the same. Female, aged 30-39 years
5 [Generic medicines] work the same therapeutically, but I suppose people just have this notion that if it’s cheaper it can’t be as good—that’s the patients per-
ception of it I think. Female, aged 30-39 years
6 I think, to be honest, any time [a patient has] had a problem with a generic instead of a brand is because they feel that they’re being cheated; they basically 
feel that they’re getting second best because it’s cheaper. Female, aged 30-39 years
7 I think if [the patient] started on a generic, and it’s what they know, they prefer that; so I think that it’s maybe the change—it’s a change management issue 
more than anything else. Male, aged 40-49 years
8 One woman I can’t convince that the generic coated aspirin would not have caused her to bleed, it’s totally in her mind; you can’t win those battles.  
Male, aged 50-64 years
9 [If] you know what a patient is satisfied with, you generally won’t rock their boat. Female, aged over 65 years
10 The first thing I would do is I’d try and explain the situation but . . . at the end of the day, I think quite often with people who are coming in, they’ve made up 
their mind and there’s really very little you can do at that stage. Male, aged 30-39 years
11 You try to explain to them that it is exactly the same medication and explain to them that it’s the same amount of drug, just called something else, that 500 
milligrams of the generic drug is exactly the same, that it’s made in the same way, but then if they’re still going “no, no, no,” we’d give them the original. 
Female, aged 30-39 years
12 There have been an increasing number of incidences where people have come back and said that the quality of the solid dosage form is significantly poorer, 
and there is one company who are particularly culpable in this regard, whereby their tablets crumble on punching from a blister pack. Their capsules are 
virtually impossible to get out of the blister pack. Now that’s not to say that there’s anything wrong with the actual raw ingredient, with the medication within 
the solid dosage form, but there are significant shortcomings in the way those solid dosage forms are compounded. And I think that if it’s not rectified, it is 
going to compromise patients’ attitudes towards generic medicines. Male, aged 40-49 years
13 I’ve had a couple of issues with a few [generic] tables—they have disintegrated, over time, and that problem didn’t arise with the original drug . . . but 99% 
of the time there’s no issue with the quality of [generics]. Female, aged 30-39 years
14 Packaging-wise, you definitely notice a difference with some of the generics, that you wouldn’t have half as much detail on the packaging, the boxes are quite 
plain. I know some customers will only take [the originator] tablets that actually have the label Monday, Tuesday, Wednesday at the back of them, and a lot 
of generics won’t have any of that detail on the [foil]. Female, aged 30-39 years
15 I’d like the generic companies to package their stuff better; if it’s packaged shabbily it gives a bad impression. Now I know it’s nothing to do with the effectivity 
of the substance, but some of them are very poorly packaged. Male, aged over 65 years
16 My grandmother in law . . . was on a generic simvastatin which was changed to another simvastatin which happened to be the same color and shape, with no 
markings, as her blood pressure tablet, and she ended up taking double blood pressure tablets for about 2 weeks. Male, aged 30-39 years
17 If the demographic of patients you deal with are elderly people, and you know they just don’t like change, they want to stay the same, so you’re kind of on the 
back foot immediately if you’re trying a new drug. Male, aged 30-39 years
18 Quotation from a non-Irish pharmacist: My experience with the Irish psyche is that they’re very brand oriented. I don’t know why, but they tend to be 
very brand oriented. And, I think that could be impacting on why they don’t like generics; they like the original brand . . . but as soon as you tell them it’s a 
copy, it’s a generic, they will think it’s a second-class drug. Male, aged 40-49 years
19 I just think people are very used to getting brands; they think all brands are better. It can be to do with the prescribers; some doctors prescribe a brand 
because that’s what they’ve always known. Male, aged 18-29 years
20 I think that private patients, paying themselves, don’t mind, but that the people that don’t have to pay are the ones that want to stick to the original brand…. 
It’s GMS [General Medical Services] patients that have a problem with it, not the private patients. Female, aged 30-39 years
21 I think an awful lot of people have it in their head that the generic isn’t as good. As well, medical card patients have commented a few times, ‘It’s because I’m 
on a medical card that you’re giving me the cheaper tablet.’ That’s the kind of presumption I think that’s out there—people think that because it’s cheaper, 
they don’t see generic as equivalent, but as a lesser tablet. Female, aged 30-39 years
22 Get rid of branded generics . . . either it’s a generic or its not; there’s no need for the middle ground of a branded generic. Female, aged 30-39 years
TABLE 3 Supporting Quotations from Pharmacists
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Pharmacist Experiences with Patient Complaints Regarding 
Generic Medicines
Of the 44 pharmacists, 39 (89%) reported receiving patient 
complaints associated with use of a generic medicine. Of the 
5 pharmacists who did not experienced these complaints, 1 
pharmacist did not dispense generics. Pharmacists reported 
that when patients had issues with generics, the main experi-
ences described were that the generics were not as effective or 
that the patients experienced altered or increased side effects. 
Twenty-eight pharmacists (64%) expressed an opinion that 
at least some of the negative experiences reported by patients 
were not actual, but rather were caused by a nocebo effect 
(i.e., patients’ preconceived ideas as to a perceived substandard 
nature of generics led to them having negative experiences 
with generics) rather than an actual issue with the medication 
(reference quotations 4-6, Table 3).
Medication types most reported as being problematic 
included protein pump inhibitors (27%, 12/44), statins (18%, 
8/44), inhalers (7%, 3/44), antihypertensives (7%, 3/44), anti-
biotics (7%, 3/44), antidepressants (5%, 2/44), and analgesics 
(2%, 1/44).
Conversely, 11 pharmacists (25%) stated that a patient had 
reported an issue with an originator medicine compared with 
a generic. In most cases, since the patient had received the 
generic before the originator medication, pharmacists indi-
cated that, in their opinion, the patient’s preference is often for 
the medicine first encountered and that such issues are more 
likely to be due to a change having occurred, rather than an 
actual issue with the medicine (reference quotation 7, Table 3).
In the situation where pharmacists received complaints 
from patients related to use of generic medicine and the 
patients requested the originator instead, 34 pharmacists 
(77%) stated that they would accede to the patients’ preferences 
(reference quotations 8-9, Table 3). Only 9 pharmacists (21%) 
stated that they would attempt to educate the patient (reference 
quotations 10-11, Table 3).
When asked about the differences between an originator 
and an equivalent generic, 2 pharmacists (5%) felt that there 
was no difference. Given that the only requirement for simi-
larity (in terms of ingredients) between an originator product 
and a generic equivalent is that the same active ingredient be 
used (excipients may vary) and that generic products are often 
aesthetically different from the originator, patients can be con-
fused if the differences in appearance and excipient content are 
not adequately explained to them.
Opinions Regarding Low Historic Usage of Generics
When asked why usage of generics in Ireland has been low in 
the past, the main reasons given by pharmacists were as follows: 
•	 Lack	 of	 generic	 prescribing	 (31%,	 27/44).	 The	 primary	
reasons given for this opinion were familiarity with trade 
names on the part of prescribers and their lack of knowl-
edge of the generic names of medicines.
Group Gender Age
Pharmacists
N = 44
M F 18-29 30-39 40-49 50-64 65+
23 21 9 17 10 5 3
TABLE 4 Demographics
Quotation 
Number Quotation
23 Bring it on—pharmacists have been waiting for it for years; we have absolutely no problem, we’re here ready to go, just give us the guidelines and let us just 
work on it. I’m all about value, we have to be; as professionals and as people that are actually concerned about people’s health and their finances, we want to 
give the best value. We’re not in the business of trying to rip people off, so give us that law so we can do what we’re supposed to do—which is look after our 
customers in every way possible and make them feel better. Female, aged 30-39 years
24 I can envisage that people will have issues because we’ve had issues before with people, and when it does come to it, I’d say there is a certain percentage of 
the population that won’t be happy with taking the generic one or whatever one is the best price at the time because they’re just comfortable taking their one 
particular brand and that’s it. Female, aged 30-39 years
25 I’ve had some cases [of patient complaints] where it’s actually, say, the Pfizer atorvastatin generic, comes off the same line as Lipitor; the only thing you can 
blame is patient perception when it’s exactly the same thing. Even after I told [the patient] they’re the same thing, and you know what they said: “They left 
some of the good stuff out though.” Male, aged 30-39 years
26 I think maybe a lot of the time “generic” and “cheaper” are put in the same sentence, so people think because it’s cheaper it can’t be as good as the original. 
Male, aged 30-39 years
27 I did have one particular incident where [a patient] reported [a problem with a generic] and [the medication] was actually exactly the same thing; it was a 
parallel import as opposed to a generic. They saw the pack was different, and they said [the medicine] didn’t work the same, they didn’t want that, but it was, 
in every sense, exactly the same medication. Female, aged 30-39 years
TABLE 3 Supporting Quotations from Pharmacists (continued)
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persons who are unable, without undue financial hardship, 
to arrange general practitioner, medical, or surgical services. 
Having a medical card entitles holders and their dependents to 
a number of free services, including prescription medicines (a 
dispensing charge applies to prescription medicines). In quar-
ter 4 of 2013 approximately 40% of the Irish population were 
holders of medical cards.17 Furthermore, some pharmacists felt 
that branding of generics should be disallowed because it is 
contrary to the intent of having generic medication and made 
it necessary for them to stock multiple “brands” of the same 
generic medication (reference quotation 22, Table 3).
Opinions Regarding New Legislation
All of the pharmacists interviewed were aware of the Irish gov-
ernment’s plan to introduce reference pricing and generic sub-
stitution in Ireland. When asked about their opinions about the 
new legislation, 35 pharmacists (80%) indicated that they felt 
positive about the legislation or were accepting of it. Twenty-
four pharmacists (55%) were of the opinion that it made 
financial sense and was necessary for the country, although 20 
pharmacists (46%) expressed concerns and reported that they 
anticipated issues with its practical implementation (reference 
quotations 23-24, Table 3).
■■  Discussion
According to a PubMed search in January 2014, Irish pharma-
cists’ perceptions of generic medicines have not been studied 
in the past. Internationally, a limited number of assessments 
have taken place for such countries as New Zealand,9 Portugal,4 
South Africa,5 Malaysia,8 France,10 and Sweden6 that included 
studies on views held regarding specific medication types, such 
as antiepileptic drugs7 and inhalers.3 Given the major changes 
currently underway in the Irish health care system (i.e., the 
introduction for the first time of reference pricing and generic 
substitution), the opinions and behaviors of this critical stake-
holder group have the potential to be pivotal to the success or 
failure of the changes being implemented. 
In contrast to other reports of reticent pharmacist views,3,8,9 
this study has shown that Irish pharmacists were generally 
positive towards, and accepting of, generic medicines, with 
many holding the view that they are as effective as the origina-
tor, with the exception of nonsubstitutable situations—such as 
with Narrow Therapeutic Index drugs— and that differences 
in presentation can be a source of problems for some patients. 
Very few pharmacists expressed reticent opinions, but 1 of the 
primary concerns, as has been reported elsewhere,6 was that 
confusion caused by differing aesthetic presentations of generic 
medicines has the potential to be problematic for patients. 
•	 Lack	of	government	incentive	or	pressure	for	generics	usage	
(50%, 22/44).
•	 The	 influence	 of	 the	 pharmaceutical	 industry	 (i.e,	 propri-
etary manufacturers) in Ireland (41%, 18/44).
•	 Poor	understanding	of	generics	by	consumers	(41%,	18/44).
•	 Brand	consciousness	or	loyalty	on	the	part	of	the	consumer,	
including being used to a particular brand and having poor 
cost consciousness (39%, 17/44).
•	 The	nonallowance	of	generic	substitution	(32%,	14/44).	
Pharmacist Perceptions of Quality and  
Patient Issues with Generic Medicines
Three pharmacists (7%) reported having experienced qual-
ity issues with generic medicines. Issues reported included 
crumbling tablets and having difficulty getting tablets out of 
blister packs. The pharmacists reported that, in their opinion, 
these issues affect consumer confidence in generic products 
(reference quotations 12-13, Table 3). Poorer packaging was 
also mentioned by 4 pharmacists (9%) as being perceived as 
a negative, and 1 pharmacist (2.3%) stated, anecdotally, that 
differences between originator and generic packaging can 
even cause issues for patients (e.g., where an originator brand 
tablet had the days of the week printed on the foil, serving as 
a reminder to the patient as to whether that day’s medication 
had been taken or not, but similar printing was not available 
with the generics). This led to patient preference for the origi-
nator medicine (reference quotations 14-15, Table 3). Nineteen 
pharmacists (43.2%) also reported the opinion that patients are 
sometimes resistant to change and that the different aesthetic 
presentation of generics can cause confusion and medication 
errors for some patients, particularly the elderly (reference 
quotations 20-21, Table 3).
Consequently, patient education was seen as a necessary 
step for wider acceptance of generics, and 15 pharmacists 
(34%) stated that, in their opinion, patients see generics as 
being a substandard, or lesser, alternative because they are 
cheaper, which is described as “own-brand syndrome.” Indeed, 
16 pharmacists (36%) expressed the opinion that Irish patients 
hold a significant preference for branded medications (refer-
ence quotations 18-19, Table 3).
Five pharmacists (11.4%) reported having patients who 
asked for cheaper generics. This was a minority of cases and 
tended to be limited to private patients, who, according to 
the pharmacists, have a better understanding and education 
regarding generics. Pharmacists additionally made reference 
to General Medical Services (GMS) patients getting more 
branded medication than private (i.e., self-paying) patients 
(reference quotations 20-21, Table 3). In Ireland, the GMS, or 
medical card, scheme is a means-tested scheme available to 
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Additionally, generics manufacturers/licence holders may 
play a role in improving the opinions of consumers regarding 
their products. One aspect could be to ensure that packaging 
is of a standard at least equivalent to that of the originator and, 
where relevant, to ensure that it provides the same facilities for 
prompting/reminding of patients to take the medication (e.g., 
the anecdote where a pharmacist stated that continued use of 1 
proprietary brand was due to patient preference for the packag-
ing, as the days of the week were printed on the blister pack 
foil). An argument can be made for regulators approving generic 
medicines to require that if patient aids are part of the origina-
tor packaging, any generic equivalents must provide similar 
aids in order to obtain a marketing authorization. Moreover, a 
theme emerged on the topic of branded generics: while generic 
substitution makes the issue of pharmacists needing stocks of 
multiple branded generics moot, (that is, unless a “do not sub-
stitute” prescription has been written), pharmacists expressed 
views that branding of generics should not be permitted as, 
practical aspects aside, branding of generic medications is not 
in keeping with the intention of provision of generic medicines. 
Indeed, a recent report from the Irish Economic and Social 
Research Institute on the costing of generics in Ireland has 
shown them to be similar to the original branded medication, 
thereby not resulting in substantial benefit to either the Irish 
exchequer or consumer.18
Since improved consumer confidence in generics was 
considered to be one of the major hurdles to be overcome in 
improving use of generics in Ireland (similarly noted in other 
studies4-6), the question was posed by pharmacists: How can 
this information/education be provided in a manner that is 
easy for patients to access and understand? While 1 pharma-
cist showed a patient both the originator and generic products 
side by side to prove their equivalency (in the case of asthma 
inhalers), the practicality of doing this on a day-to-day, patient-
to-patient basis is obviously something that busy pharmacists 
cannot undertake. Provision of educational supports could be 
facilitated, for example, by use of a novel tool, recently pub-
lished by our group, based on optimized quality of informa-
tion and reading ability, for development of websites providing 
health care information.19 The resulting availability of easy-to-
read handouts/pamphlets, websites, or similar sources of infor-
mation may not only provide consumers with the information 
to dispel myths about generics and, hence, improve their con-
fidence but may also have the dual effect of making the role of 
the pharmacist easier during a time of upheaval and change.
While a majority of pharmacists were in favor of the new 
legislation (with references made to the United Kingdom situ-
ation: that no clinical issues linked to a much greater use of 
generic medicines are seen, thus, the same situation could rea-
sonably be expected in Ireland without risk to patients) about 
half of the pharmacists interviewed (46%, 20/44) expressed 
concerns as to the practical implementation of associated 
changes. Concerns included the impact on the running of the 
pharmacy as well as on patients. Pharmacists felt that they 
could meet considerable resistance from patients and that they, 
being at the “coal face,” may need to spend substantial periods 
of time explaining the new system to patients, if adequate 
educative interventions are not put in place by either the gov-
ernment or other interested bodies (e.g., the Pharmaceutical 
Society of Ireland). Indeed, the requirement for education of 
the general public to improve opinions and, therefore, increase 
patient acceptance of generics was a recurring theme in this 
study, as it has been in other studies.4-6,10 Increased public 
awareness and education were considered to be fundamental 
to improved acceptance of generics by consumers. In fact, an 
anecdote told by a pharmacist, regarding how she convinced a 
patient who was reticent to take a generic version of an inhaler, 
is indicative of how such an intervention might work. The 
pharmacist told how she brought out both the generic and the 
proprietary inhalers and showed both to the patient, point-
ing out the ingredients of both and showing the patient that 
they were the same. This practical demonstration of equiva-
lence convinced the patient to try the generic inhaler, and the 
pharmacist indicated that the patient did not return with any 
subsequent issues. Such examples should be made use of when 
designing educational interventions for patients. 
Patient preference was seen to have a considerable influ-
ence on dispensing practices, with many pharmacists (77%, 
34/44) acceding to patients’ wishes for brand-name medica-
tions, despite the fact that pharmacists believed the majority 
of issues/complaints from patients regarding generics are not 
actual, but rather due to the nocebo effect, that is, patients’ 
prejudices regarding generic medicines (reference quotation 
25, Table 3). Pharmacists were of the opinion that this nega-
tive patient perception may be based on the fact that generics 
are less expensive so, therefore, cannot be as good (reference 
quotation 26, Table 3). Also, pharmacists believed that many 
negative patient experiences were due to changes in medica-
tion and that the first medication that the patient is exposed 
to will tend to be the preferred option. Therefore, when this 
is changed, the patient is more likely to experience a problem 
(reference quotation 27, Table 3).
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Limitations
A possible limitation of this study could be in the selection of 
participants. All of the pharmacists interviewed were commu-
nity pharmacists, whose opinions may differ from pharmacists 
working in hospitals or other settings. Furthermore, differing 
interview settings (some participants were interviewed face-to-
face, and others were interviewed over the telephone) might 
have influenced the data gathered in this study.20 However, 
review and comparison of the themes emerging from partici-
pants interviewed in different settings did not show any sub-
stantial difference in the opinions, perceptions, and behaviors 
expressed between participants. Moreover, while the authors 
acknowledge that quantification of qualitative data is some-
times contentious, we chose to adopt this approach in order to 
best provide easy visualization of results and offer a more com-
prehensive insight into the patient perspective. The strengths 
of such an approach have been discussed by Schonfelder in 
2011.21 
A strength of this study is the number of subjects used for 
qualitative interview; the number of participants in this study 
compared favorably with the only other semistructured inter-
view-based studies that could be found in PubMed (i.e., 16 par-
ticipants were interviewed for an analogous study in Sweden6 
and 6 pharmacists (from a total of 15 health care professionals) 
were interviewed for a similar study in South Africa5).
■■  Conclusions
Community pharmacists in Ireland hold positive opinions 
about usage of generic medicines, yet they have concerns about 
the practical implementation of reference pricing and generic 
substitution. Concerns were also raised about the impact on 
patient acceptance due to the varying appearance of generic 
medicines and regarding the lack of confidence that they 
observed in the general public in relation to usage of generic 
medicines. 
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